BELLUS Health Inc. – “The Perils Of A Big Pharma Partnership”

NEW YORK, NY / ACCESSWIRE / December 1, 2015 / BELLUS Health Inc. (TSX: BLU) (OTC: BLUSF) today published a new blog post on The Chairman’s Blog, written by the Company’s President and Chief Executive Officer, Roberto Bellini. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his new post, Mr. Bellini addresses the recently announced mega merger of Pfizer and Allergan and what it can potentially mean for biotech partnerships. He goes on to discuss some of the inherent risks of partnering with big pharma, and highlights the essential qualities of an effective partnership. Read the full blog post from Mr. Bellini on TheChairmansBlog.com (http://www.thechairmansblog.com/bellus-health-inc/roberto-bellini/the-perils-of-a-big-pharma-partnership/).

About BELLUS Health Inc.

BELLUS Health is a drug development company focused on rare diseases. Its pipeline of rare disease projects includes KIACTA(TM) in Phase III for AA amyloidosis, KIACTA(TM) for sarcoidosis, clinical stage Shigamab(TM) for sHUS and a research-stage project for AL amyloidosis. The lead program KIACTA(TM) is currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTA(TM).

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com

SOURCE: TheChairmansBlog.com

ReleaseID: 434227